Why the study?
Self-expanding supra-annular TAVR valves show better hemodynamics and durability at 5 years than SAVR, prompting investigation into whether these benefits can be achieved surgically.
Does surgical implantation of a transcatheter self-expanding supra-annular valve result in successful procedural and hemodynamic outcomes in patients undergoing SAVR?
Does surgical implantation of a transcatheter self-expanding supra-annular valve result in successful procedural and hemodynamic outcomes in patients undergoing SAVR?
Answers are grounded in this paper and cite their sources.
Surgical implantation of a transcatheter self-expanding supra-annular valve is feasible and yields excellent early hemodynamics in patients undergoing surgical aortic valve replacement.
The transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve has shown better hemodynamic outcomes and better valve durability at 5 years when compared with a surgical aortic valve replacement (SAVR). It is possible that the benefits of a self-expanding supra-annular valve can be achieved using a surgical approach. An Evolut (Medtronic) transcatheter aortic valve was surgically implanted in 4 patients undergoing SAVR. Standard surgical methods were used. Three patients had native aortic valve disease, and 1 patient had a degenerated surgical bioprosthesis. The measured valve size was 21 mm in 3 patients and 23 mm in 1 patient; all received a 29-mm Evolut. No valve migration was observed. No patients required a pacemaker. Discharge echocardiography showed low aortic valve gradients (arithmetic mean of 5.3 mm Hg). One patient had a mild paravalvular leak. SAVR using a self-expanding supra-annular valve can be successfully performed in patients not amenable to TAVR.
No takes yet. Share an insight, caveat, or question.
O’Hair et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: